The development of IL-6R superantagonists should allow the role of IL-6 in hormone-dependent and -independent conditions, such as breast and prostate cancer, to be elucidated and may lead to their use as novel therapeutic options for their treatment. This evidence concerns the gene IL6 and prostate carcinoma.